New drug combo shows promise for tough blood cancers
NCT ID NCT01869114
First seen Jan 11, 2026 · Last updated May 01, 2026 · Updated 16 times
Summary
This study tested a combination of two drugs, azacitidine and sirolimus, in 57 adults with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that came back or couldn't be treated with strong chemotherapy. The goal was to see if the combination could shrink or control the cancer. The approach uses sirolimus to block cancer cell growth and azacitidine to kill cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ADULT ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Abington Hospital - Jefferson Health
Abington, Pennsylvania, 19001, United States
-
Jefferson Health NJ Division (Kennedy Hospital)
Sewell, New Jersey, 08012, United States
-
Jefferson Health, Aria Hospital
Philadelphia, Pennsylvania, 19124, United States
-
Jefferson Health, Methodist Hospital
Philadelphia, Pennsylvania, 19148, United States
-
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.